Vimarsana
Biggest News Aggregation in the World

Page 2 - Negative Predictive Value News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Negative Predictive Value. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Negative Predictive Value Today - Breaking & Trending Today

Vesica Health Announces the Appointment of Recognized Industry Leaders to Newly Formed Board of Directors - Vimarsana News

Vesica Health Announces the Appointment of Recognized Industry Leaders to Newly Formed Board of Directors

/PRNewswire/ -- VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection...

Biovica International: DiviTum TKa Clinical Validation Data Published in Biomarkers - Vimarsana News

Biovica International: DiviTum TKa Clinical Validation Data Published in Biomarkers

UPPSALA, SE / ACCESSWIRE / January 31, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces that results clinically validating the

SMALL CAP MOVERS: Xeros Technology jumps; Tekmar slumps - Vimarsana News

SMALL CAP MOVERS: Xeros Technology jumps; Tekmar slumps

Xeros Technology was the week's best performer as the licensing agreement for its XFilter filtration technology with Hanning Elektro-Werke got the market excited.

Investegate |Verici Dx PLC Announcements | Verici Dx PLC: Further data from TutevaT validation study - Vimarsana News

Investegate |Verici Dx PLC Announcements | Verici Dx PLC: Further data from TutevaT validation study

Investegate announcements from Verici Dx PLC, Further data from TutevaT validation study

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong - Vimarsana News

Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the only cancer screening test approved by the National Medical Products Administration (NMPA) HONG KONG, June 9, 2022 /PRNewswire/ --Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test - ColoClear by Circle (Co...